Page last updated: 2024-10-30

maprotiline and Neuroleptic Malignant Syndrome

maprotiline has been researched along with Neuroleptic Malignant Syndrome in 1 studies

Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.

Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ohkoshi, N1
Satoh, D1
Nishi, M1
Shoji, S1

Other Studies

1 other study available for maprotiline and Neuroleptic Malignant Syndrome

ArticleYear
Neuroleptic malignant-like syndrome due to donepezil and maprotiline.
    Neurology, 2003, Mar-25, Volume: 60, Issue:6

    Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Cholinesterase Inhibitors; Donepe

2003